A5100432064- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Viral-associated cancers and disorders
- Childhood Cancer Survivors' Quality of Life
- CNS Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Sarcoma Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Monoclonal and Polyclonal Antibodies Research
- Medical Imaging Techniques and Applications
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cutaneous lymphoproliferative disorders research
- Prostate Cancer Treatment and Research
- RNA modifications and cancer
- Prostate Cancer Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Urologic and reproductive health conditions
- 14-3-3 protein interactions
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Histone Deacetylase Inhibitors Research
Guangxi Medicinal Botanical Garden
2024-2025
City of Hope
2017-2024
City Of Hope National Medical Center
2017-2024
Ruijin Hospital
2017-2024
Shanghai Jiao Tong University
2024
Peking University
2023
Peking University Third Hospital
2023
Cancer Research And Biostatistics
2022
Children's Oncology Group
2009-2021
Beckman Research Institute
2017-2021
The Children's Oncology Group study AHOD0031, a randomized phase III study, was designed to evaluate the role of early chemotherapy response in tailoring subsequent therapy pediatric intermediate-risk Hodgkin lymphoma. To avoid treatment-associated risks that compromise long-term health and maintain high cure rates, dose-intensive with limited cumulative doses used.Patients received two cycles doxorubicin, bleomycin, vincristine, etoposide, cyclophosphamide, prednisone (ABVE-PC) followed by...
In 1995, the Children's Cancer Group (CCG) opened a trial for patients with Hodgkin's lymphoma evaluating whether low-dose involved-field radiation therapy (IFRT) improved event-free survival (EFS) achieving complete response after chemotherapy. We present long-term study outcome using final data through March 2007.
Mantle cell lymphoma (MCL) is a phenotypically and genetically heterogeneous malignancy in which the genetic alterations determining clinical indications are not fully understood. Here, we performed comprehensive whole-exome sequencing analysis of 152 primary samples derived from 134 MCL patients, including longitudinal 16 patients matched RNA-Seq data 48 samples. We classified into 4 robust clusters (C1-C4). C1 featured mutated immunoglobulin heavy variable (IGHV), CCND1 mutation,...
PURPOSE Children with Hodgkin's lymphoma (HL) routinely undergo surveillance computed tomography (CT) imaging for up to 5 years after therapy, resulting in cost and radiation exposure, without clear benefit. The objective of this study was determine the contribution CT, as compared clinical findings, detection disease recurrence. PATIENTS AND METHODS Two hundred sixteen patients, age ≤ 21 old, were treated on multicenter Pediatric Oncology Group 9425 trial. Data patients who experienced...
Children's Oncology Group study AHOD03P1 was designed to determine whether excellent outcomes can be maintained for patients with low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma (LPHL) a strategy of resection alone or minimal chemotherapy.Patients stage IA LPHL in single node that completely resected were observed without further therapy; recurrences treated three cycles doxorubicin/vincristine/prednisone/cyclophosphamide (AV-PC). Patients unresected IIA AV-PC. less than complete...
Abstract Purpose: In classical Hodgkin lymphoma, the malignant Reed–Sternberg cells express cell surface marker CD30. Brentuximab vedotin is an antibody–drug conjugate (ADC) that selectively delivers a potent cytotoxic agent, monomethyl auristatin E (MMAE), to CD30-positive cells. Although brentuximab elicits high response rate (75%) in relapsed/refractory most patients who respond eventually develop resistance. Patients and Methods: We developed two vedotin–resistant lymphoma line models...
Background Early response to initial chemotherapy in Hodgkin lymphoma (HL) measured by computed tomography (CT) and/or positron emission (PET) after two three cycles of may inform therapeutic decisions. Risk stratification at diagnosis could, however, allow earlier and potentially more efficacious treatment modifications. Patients Methods We developed a predictive model for event-free survival (EFS) pediatric/adolescent HL using clinical data known from 1103 intermediate-risk patients...
There is no clear consensus between pediatric and adult providers about the treatment of adolescents young adults (AYAs) with Hodgkin lymphoma (HL).Failure-free survival (FFS) overall (OS) were compared 114 patients ages 17 to 21 years HL who treated on Eastern Cooperative Oncology Group-American College Radiology Imaging Network Intergroup E2496 study 391 similarly Children's Group (COG) AHOD0031 study.Comparing AYAs from COG studies, there significant differences in extralymphatic disease,...
BACKGROUND The Children's Oncology Group AHOD0431 study evaluated a response‐directed treatment paradigm in which minimal initial chemotherapy and low‐dose radiation was received only by patients who did not achieve complete remission, chemotherapy/low‐dose salvage regimen those had protocol‐defined, low‐risk recurrence. METHODS Patients younger than 21 years stage IA or IIA nonbulky disease were eligible. strategy determining the proportion that alone, first second remission without receipt...
Abstract Purpose: We performed detailed genomic analysis on 87 cases of de novo diffuse large B-cell lymphoma germinal center type (GCB DLBCL) to identify characteristics that are associated with survival in those treated R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Experimental Design: The were extensively characterized by combining the results IHC, cell-of-origin gene expression profiling (GEP; NanoString), double-hit GEP (DLBCL90), FISH cytogenetic for...
The Children's Oncology Group conducted this phase II study to assess the efficacy and toxicity of gemcitabine vinorelbine (GV) in pediatric patients with heavily pretreated relapsed/refractory Hodgkin's disease. Both agents have significant single-agent response rates setting.
Aims: The primary objective of this study is to explore the impact Ganfule (GFL), a traditional Chinese medicine, on differentially expressed genes (DEGs) linked nonalcoholic fatty liver disease (NAFLD). By identifying potential biomarkers, we seek enhance GFL's clinical efficacy through targeted pharmaceutical design. Background: NAFLD prevalent disorder, often associated with obesity and metabolic syndrome. While GFL has demonstrated in treating NAFLD, its precise targets mechanisms action...
Assay of cell-free DNA in blood offers an approach to assessment tumor DNA. We sought determine whether Epstein-Barr virus (EBV) is also a good surrogate for the presence children with Hodgkin lymphoma, as it adults, and correlates pediatric outcomes. Pediatric patients enrolled Children's Oncology Group trial (AHOD0031) were studied at baseline 8 days after initiation treatment. At baseline, EBV correlated tumor, therapy predicted inferior event-free survival. warrants further investigation...
Abstract Background Treatment of pediatric lymphocyte‐predominant Hodgkin lymphoma (LPHL) is controversial but has typically consisted both chemotherapy and radiation. Radiation therapy associated with potential late effects in children adolescents. We examined the impact radiation on long‐term outcome patients LPHL treated CCG‐5942, a large cooperative group study (HL). Procedure Eighty‐two were registered CCG‐5942. Fifty‐two (63%) received alone; 29 (35%) followed by involved‐field (IFRT)....
A Children's Oncology Group clinical trial aimed to determine if bortezomib (B) increased the efficacy of ifosfamide and vinorelbine (IV) in paediatric Hodgkin lymphoma (HL). This study enrolled 26 relapsed HL patients (<30 years) treated with two four cycles IVB. The primary endpoint was anatomic complete response (CR) after cycles. Secondary endpoints included overall (OR: CR + partial response) at completion compared historical controls [72%; 95% confidence interval (CI): 59-83%]....